CT52923,98.58%
产品编号：Bellancom-148514| CAS NO：205256-55-9| 分子式：C23H25N5O4S| 分子量：467.54
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，
CT52923
| 产品介绍 | CT52923 是一种选择性的血小板衍生生长因子受体 (PDGFR) 拮抗剂，具有口服活性。CT52923 也是一种 ATP 竞争性抑制剂。CT52923 可用于病理疾病的研究，包括动脉粥样硬化、肾小球肾炎、肝硬化、肺纤维化和癌症。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 生物活性 | CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer. | ||||||||
| 体外研究 |
CT52923 抑制 PDGFRs 和干细胞因子受体，IC50 值为 100 至 200 nM。 西域 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Migration Assay
|
||||||||
| 体内研究 (In Vivo) |
CT52923（口服；5、15、30 和 50 mg/kg；每日两次）可显著抑制大鼠颈动脉损伤后内膜新生的形成。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 体内研究 |
CT52923（口服；5、15、30 和 50 mg/kg；每日两次）可显著抑制大鼠颈动脉损伤后内膜新生的形成。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 体内研究 |
CT52923（口服；5、15、30 和 50 mg/kg；每日两次）可显著抑制大鼠颈动脉损伤后内膜新生的形成。 西域 has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||
| 性状 | Solid | ||||||||
| 溶解性数据 | |||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
| 储存方式 |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||
| 参考文献 |
浙公网安备 33010802013016号